Core Viewpoint - Clearmind Medicine Inc. has initiated its U.S. clinical trial for its psychedelic-derived treatment CMND-100 aimed at addressing Alcohol Use Disorder (AUD), marking a significant step in the development of innovative therapies for this under-treated health issue [1][3]. Group 1: Clinical Trial Details - The clinical trial site at Yale School of Medicine's Department of Psychiatry has been activated, with patient enrollment set to begin [1]. - The trial will be led by Dr. Anahita Bassir Nia, M.D., and will also take place at Johns Hopkins University School of Medicine and the IMCA Center in Israel [2]. Group 2: Company Overview and Objectives - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health problems, including AUD [4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites